Drug-review deadlines and safety problems

New England Journal of Medicine

Volumn 358, Issue 13, 2008, Pages 1354-1361

  Carpenter, Daniel ^a,d   Zucker, Evan James ^b   Avorn, Jerry ^b,c  

^a HARVARD UNIVERSITY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CORRELATION ANALYSIS; DECISION MAKING; DRUG APPROVAL; DRUG RESEARCH; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; LOGISTIC REGRESSION ANALYSIS; MEDICAL PRACTICE ACT; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; DRUG CONTROL; DRUG INDUSTRY; DRUG LABELING; DRUG TOXICITY; ECONOMICS; GOVERNMENT REGULATION; LEGAL ASPECT; METHODOLOGY; POSTMARKETING SURVEILLANCE; STATISTICS; TIME; UNITED STATES;

DRUG AND NARCOTIC CONTROL; DRUG APPROVAL; DRUG INDUSTRY; DRUG LABELING; DRUG TOXICITY; GOVERNMENT REGULATION; PRODUCT SURVEILLANCE, POSTMARKETING; TIME FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 41449104685     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMsa0706341     Document Type: Article

References (32)

1. Woodcock J. Drug safety and the drug approval process: hearings before the Senate Committee on Health, Education, Labor and Pensions, March 3, 2005. Washington, DC: Department of Health and Human Services. (Accessed March 3, 2008, at http://www.hhs.gov/asl/testify/t050303b.html.)
2. Olson MK. Managing delegation in the FDA: reducing delay in new-drug review. J Health Polit Policy Law 2004;29:397-430.
3. Lewis C. FDA begins product approval initiative. FDA Consumer, May-June 2003.
4. FDA Office of Planning. Report on PDUFA goals: original new product applications. Rockville, MD: Food and Drug Administration. (Accessed March 3, 2008, at http://69.20.19.211/oc/pdufa/report2002/2002-onpa.html.)
5. FDA Office of the Commissioner. Performance on FY99 FDAMA Goals. Rockville, MD: Food and Drug Administration. (Accessed March 3, 2008, at http://www.fda.gov/oc/fdama/fdamaplnresponse/rptgoalsFY99.html.)
6. Prescription Drug User Fee Act (PDUFA): adding resources and improving performance in FDA review of new drug applications. Rockville, MD: Food and Drug Administration, November 2005. (Accessed March 3, 2008, at http://www.fda.gov/ oc/pdufa/whitepaper11-10/whitepaper11-10.html.)
7. Horton R. Lotronex and the FDA: a fatal erosion of integrity. Lancet 2001;357:1544-5.
8. Avorn J. Powerful medicines: the benefits, risks, and costs of prescription drugs. New York: Knopf, 2004.
9. Okie S. What ails the FDA? N Engl J Med 2005;352:1063-6. [Erratum, N Engl J Med 2005;352:2563.]
10. Ray WA, Stein CM. Reform of drug regulation - beyond an independent drug-safety board. N Engl J Med 2006;354:194-201.
11. Fontanarosa PB, Rennie D, De Angelis CD. Postmarketing surveillance - lack of vigilance, lack of trust. JAMA 2004;292:2647-50.
12. Topol EJ. Failing the public health - Merck, rofecoxib, and the FDA. N Engl J Med 2004;351:1707-9.
13. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71. [Erratum, N Engl J Med 2007;357:100.]
14. Union of Concerned Scientists. Voices of scientists at FDA: protecting public health depends on independent science. 2006. (Accessed March 3, 2008, at http://www.ucsusa.org/assets/documents/scientific_integrity/FDA-Survey-Brochure. pdf.)
15. McClellan M. Drug safety reform at the FDA - pendulum swing or systematic improvement? N Engl J Med 2007;356:1700-2.
16. FDA new molecular entity approval database, 1950-2004. Cambridge, MA: Department of Government, Faculty of Arts and Sciences, Harvard University. (Accessed March 3, 2008, at http://people.hmdc.harvard.edu/~dcarpent/fdaproject. html.)
17. Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model. New York: Springer, 2000.
18. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002;287:2215-20.
19. Scrip World Pharmaceutical News, Scrip Reports, 1993-2007. (Accessed March 3, 2008, at http://www.pjbpubs.com/scrip/index.htm.)
20. Pharmaprojects - pharmaceutical R&D pipeline intelligence. London: Informa UK, 2007. (Accessed March 3, 2008, at http://www.pharmaprojects.com/ research_development_analysis/.)
21. Fung M, Thornton A, Mybeck K, Hsiao-Hui J, et al. Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets - 1960 to 1999. Drug Inf J 2001;35:293-317.
22. Warnings information page. Kansas City: Kansas University Medical Center. (Accessed March 3, 2008, at http://www.formularyproductions.com/kumc/.)
23. FDA-approved drug products database. Rockville, MD: Food and Drug Administration. (Accessed March 3, 2008, at http://www.accessdata.fda.gov/ scripts/cder/drugsatfda/.)
24. PDUFA III: independent evaluation of FDA's first cycle review performance - retrospective analysis final report, January 2006. (Accessed March 3, 2008, at http://www.fda.gov/ope/pdufa/PDUFA1stCycle/pdufa1stcycle.pdf.)
25. King EN, Ryan TP. A preliminary investigation of maximum likelihood logistic regression versus exact logistic regression. Am Stat 2002;56:163-70.
26. Mehta C, Patel N. LogXact8 statistical software. Cambridge, MA: LogXact, 2007.
27. Moffitt S. Inviting outsiders in: choosing access to bureaucratic implementation. (Ph.D. dissertation. Ann Arbor: University of Michigan, 2005.)
28. Healthcare Cost and Utilization Project (HCUP). Rockville, MD: Agency for Healthcare Research and Quality, February 2007. (Accessed March 3, 2008, at www.hcup-us.ahrq.gov/overview.jsp.)
29. Committee on the Assessment of the US Drug Safety System, Baciu A, Stratton K, Burke SP, eds. The future of drug safety: promoting and protecting the health of the public. Washington, DC: National Academies Press, 2006.
30. Drug safety: improvement needed in FDA's postmarket decision-making and oversight process. Washington, DC: Government Accountability Office, 2006.
31. Carpenter D, Chernew M, Smith DG, Fendrick AM. Approval times for new drugs: does the source of funding for FDA staff matter? Health Aff (Millwood) 2003; Suppl Web Exclusives:W3-618-W3-624.
32. Ross DB. The FDA and the case of Ketek. N Engl J Med 2007;356:1601-4.